TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01339195

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: French adaptation of NINDS-Canadian Stroke Network battery
Description: * clinical: post-stroke neurological follow-up assessment~* neuropsychological: comprising the NINDS-Canadian Stroke Network neuropsychological battery~* MRI
Study: NCT02129166

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dasatinib
Description: In this group, subjects will take dasatinib only. Dose regimen: dasatinib 20 mg single oral dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib+Imatinib
Description: In this group, subjects will take imatinib prior to dasatinib administration.~Dose regimen: Imatinib: 400 mg single oral dose Dasatinib: 20 mg single oral dose
Study: NCT04234490

Intervention type: PROCEDURE
Intervention: Parenteral nutrition
Description: Impact of parenteral nutrition on patient quality of life over time and impact on carer burden
Study: NCT03532256

Intervention type: BEHAVIORAL
Intervention: Observation
Description: Patients will be contacted postoperatively via an automated text-message to assess pain, functional status, and opioid consumption.

Intervention type: BEHAVIORAL
Intervention: Observation
Description: Patients will be contacted postoperatively via an automated text-message to assess pain, functional status, and opioid consumption.

Intervention type: BEHAVIORAL
Intervention: Observation
Description: Patients will be contacted postoperatively via an automated text-message to assess pain, functional status, and opioid consumption.
Study: NCT03963492

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking
Description: Participants will undergo training in either the CONT or INT walking interventions 2x/week for 6 weeks for a total plan of 12 training sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking
Description: Participants will undergo training in either the CONT or INT walking interventions 2x/week for 6 weeks for a total plan of 12 training sessions.
Study: NCT04595045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A infiltrations
Description: Echo-guided infiltration of botulinum toxin type A (Dysport®) in the lower limbs according to normal service practice
Study: NCT03903991

Intervention type: OTHER
Intervention: Temperature recording
Description: Tympanic and oesophageal temperatures will be recorded during the procedure
Study: NCT00294866

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paricalcitol
Description: Patients randomized to either receive Paricalcitol or have it held. After 4 weeks they are switched to the opposite intervention.
Study: NCT03532256

Intervention type: BEHAVIORAL
Intervention: Text to online survey
Description: Subset of surgical patients will receive an automated text message with a link to a secure online survey with questions that assess pain, functional status, and opioid consumption.
Study: NCT00294866

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Paricalcitol
Description: Patients randomized to either receive Paricalcitol or have it held. After 4 weeks they are switched to the opposite intervention.
Study: NCT03823170

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Laser therapy
Description: The low-power, infrared (808nm wavelength) diode laser with a power of 100mW will be used. The mode of irradiation is punctual, in contact and perpendicular to the dental surface. Three points on the crown of multiradicular teeth (mesial and distal of the cervical region and central part of the tooth lesion) and two points on the crown of unirradicular teeth (central point of the cervical region and central part of the tooth lesion) will be irradiated for 10s per point , 1J per point, with a 72-hour interval between treatment sessions. The distance between the irradiation points will be about 2 mm. The tip of the laser equipment will be positioned perpendicular to the application site.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluorotherapy
Description: The treatment will be carried out with the application of fluoride varnish, with the aid of a microbrush. After the application, water will be dripped onto the applied varnish in order to promote its drying. Fluorotherapy will be performed once a week, totaling 4 sessions.
Study: NCT03532256

Intervention type: BEHAVIORAL
Intervention: Bi-directional text script
Description: Subset of surgical patients will receive an automated bi-directional text message script with questions that assess pain, functional status, and opioid consumption.
Study: NCT04342403

Intervention type: DIAGNOSTIC_TEST
Intervention: Quality of Life
Description: Quality of life instruments including King's Sarcoidosis Questionnaire (KSQ) and Sarcoidosis Assessment Tool (SAT)
Study: NCT00350857

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended-Release Carbamazepine
Study: NCT02049359

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Texting
Description: Bidirectional texting once weekly for 12 weeks
Study: NCT03823170

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Laser therapy and Fluorotherapy
Description: This group will be treated first with the laser (same specifications as Laser therapy), followed by application of fluoride varnish (same specifications as Fluorotherapy).
Study: NCT01981707

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F-Choline-PET
Study: NCT03097276

Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood sample
Description: blood sample will be collected

Intervention type: RADIATION
Group type: OTHER
Intervention: CT scan
Description: CT scan
Study: NCT02407613

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips Sonalleve MR-HIFU Breast Tumor Therapy System
Description: Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) is a completely non-invasive treatment technique. HIFU uses focused ultrasound to achieve temperature rise in the targeted tissue. Real time monitoring of the treatment with MR-thermometry is used to ensure optimal safety.
Study: NCT01541761

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family groups
Description: The group sessions are designed to facilitate on-going interaction among consistent groups of 6 - 8 parents and other care givers with infants the same age and will be coordinated with scheduled well child care visits. They will be conducted in English and Spanish. The groups will focus on nutrition and, parenting.
Study: NCT02227498

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Effect of Argus II on Functional Vision
Description: To evaluate the safety and effectiveness of the Argus II Retinal Prosthesis in subjects with AMD.
Study: NCT03512054

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standardized 5-step weaning procedure
Description: Weaning process in 5 steps (0-4), by a multi-professional team (neurosurgeon, physiotherapist, nurse, caregiver...) Stability criteria are defined for each person, after validation pass the next step. Stability criteria degradation return to the previous step. Weaning process can take back after stability criteria renormalization.~Step 0: cuff deflate. Step 1: occlusion test. Steps 0 and 1 can assess the freedom and protect capacity airway. In failure process, we can propose a nasofibroscopy.~Step 2: Phonatory Valve. Respiratory rehabilitation/ swallowing, limiting breathing effort. The valve ought to stay 12 hours before going to the step 3.~Step 3: Plug. Finish the Respiratory rehabilitation/ swallowing. The plug ought to stay 24hours minimum before going to the step 4.~Step 4: Decannulation
Study: NCT02049086

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBIRT-PM
Description: Screening, Brief Intervention and Referral to Treatment with Pain-Management advice (SBIRT-PM)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain Module
Description: The pain module of SBIRT-PM with no substance abuse focus (Pain Module Only)
Study: NCT02753400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: emixustat hydrochloride
Description: Tablet for oral administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets for oral administration contain only inactive ingredients

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets for oral administration contain only inactive ingredients
Study: NCT00217412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally
Study: NCT01164189

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (vial of 400mg/16mL) at a dose of 10 mg/kg bodyweight i.v. in 90 min on day 1 and day 14 of 4 week cycles

Intervention type: DRUG
Group type: OTHER
Intervention: Temozolomide
Description: Temozolomide (250, 100, 20 and 5 mg caps) will be administered orally on day 1-5, 150-200 mg/m², and will be repeated every 4 weeks. This will be repeated for up to 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide (250, 100, 20 and 5 mg caps) will be administered orally on day 1-5, 150-200 mg/m², and will be repeated every 4 weeks. This will be repeated for up to 12 cycles.
Study: NCT00217412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isotretinoin
Description: Given orally
Study: NCT02144584

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine XR
Description: The active drug will be encapsulated by the University of Utah Research Pharmacy to maintain blinding.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for memantine)
Description: Placebo to be capsuled to look identical to active drug (memantine)
Study: NCT01172353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium bicarbonate
Description: hydration with sodium bicarbonate 1ml/Kg/h for 6 hours
Study: NCT04646343

Intervention type: OTHER
Intervention: administration of F-CISS and F-PWES pre version
Description: the CISS questionnaire is a 6 items questionnaire, the PWES is a 3 items questionnaire. Only 10 minutes are required to fulfilled the questionnaires.

Intervention type: OTHER
Intervention: administration of definitive version of F-CISS and F-PWES plus F-DASH, F-HFS and F-SF 36
Description: The administration will required 25 minutes
Study: NCT01172353

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: hydration with saline 1ml/Kg/h for 6 hours
Study: NCT01856985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Study: NCT01841606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: 4mg of IV ondansetron

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 10mL of IV normal saline
Study: NCT00686920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Oral
Study: NCT00783679

Intervention type: DEVICE
Group type: OTHER
Intervention: NICO device
Description: Measurement of cardiac output and simultaneous blood sampling.~The subjects' cardiac output will be measured by NICO device and also by thermodilution method. Simultaneously blood samples will be drawn from the pulmonary artery catheter and arterial line. The calculated and measured cardiac output values will be compared for accuracy.
Study: NCT02345278

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SUBLIVAC FIX Mite mixture
Description: Study medication will be taken sublingually once a day. Patients will start with one drop and increase the dose by one drop each consecutive day until the maintenance dose (5 drops/day) is reached. Drops should be kept under the tongue for 2-3 minutes before swallowing. After reaching the maintenance dose patients will be treated up to 1 month.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SUBLIVAC FIX Mite mixture
Description: Study medication will be taken sublingually once a day. Patients will start with one drop and increase the dose by one drop each consecutive day until the maintenance dose (5 drops/day) is reached. Drops should be kept under the tongue for 2-3 minutes before swallowing. After reaching the maintenance dose patients will be treated up to 1 month.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SUBLIVAC FIX Mite mixture
Description: Study medication will be taken sublingually once a day. Patients will start with one drop and increase the dose by one drop each consecutive day until the maintenance dose (5 drops/day) is reached. Drops should be kept under the tongue for 2-3 minutes before swallowing. After reaching the maintenance dose patients will be treated up to 1 month.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SUBLIVAC FIX Mite mixture
Description: Study medication will be taken sublingually once a day. Patients will start with one drop and increase the dose by one drop each consecutive day until the maintenance dose (5 drops/day) is reached. Drops should be kept under the tongue for 2-3 minutes before swallowing. After reaching the maintenance dose patients will be treated up to 1 month.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study medication will be taken sublingually once a day. Patients will start with one drop and increase the dose by one drop each consecutive day until the maintenance dose (5 drops/day) is reached. Drops should be kept under the tongue for 2-3 minutes before swallowing. After reaching the maintenance dose patients will be treated up to 1 month.
Study: NCT04495777

Intervention type: OTHER
Intervention: Fonseca Anamnestic Index
Description: Fonseca Anamnestic Index was developed to assess the severity of temporomandibular disorders, based on its signs and symptoms. It has been proposed as a low cost and easy to apply alternative and has been used in screening for TMD in a non-patient population5. It was created with 10 items with 3 options of answers (specific scores): yes (10 points), sometimes (5 points) and no (0 points). The final score of the instrument is determined by the sum of the scores of all items, allowing the following classifications: the absence of signs and symptoms of TMD (0-15 points), mild TMD (20-45 points), moderate TMD (50-65 points), and severe TMD (70-100 points) (19).
Study: NCT02763579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Description: Atezolizumab intravenous infusion was administered at a dose of 1200 mg on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4) and maintenance phase (Cycle 5 onward).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo intravenous infusion was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4) and maintenance phase (Cycle 5 onward).
Study: NCT04202900

Intervention type: OTHER
Group type: OTHER
Intervention: phototherapy protocol
Description: Pretest：Common symptoms in the elderly include insomnia, depression, pressure sore wounds, blood sugar, blood pressure, body temperature,fatigue,cold limbs.~Intervention：LED light therapy for 6 weeks, 2-3 times a week, every 30 minutes. Post test：Common symptoms in the elderly include insomnia, depression, pressure sore wounds, blood sugar, blood pressure, body temperature,fatigue,cold limbs.
Study: NCT01206361

Intervention type: DRUG
Intervention: XALACOM
Description: Xalacom eye drops

Intervention type: DRUG
Intervention: Duotrav
Description: Duotrav eye drops

Intervention type: DRUG
Intervention: Ganfort
Description: Ganfort eye drops
Study: NCT03502629

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB226
Description: 3mg/kg treat every 2 weeks
Study: NCT00939133

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tretinoin microsphere 0.04% gel
Description: Applied daily to entire face for six months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle gel
Description: Placebo
Study: NCT01523795

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motion-controlled video gaming
Description: Play of motion-controlled video games for one hour

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional video gaming
Description: Participants played traditional video games for one hour

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Television watching
Description: Participants watched television for one hour
Study: NCT02970669

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sacubitril/valsartan (LCZ696)
Description: sacubitril/valsartan tablet taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan (LCZ696)
Description: sacubitril/valsartan tablet taken orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enalapril
Description: Enalapril tablet taken orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: matching placebo sacubitril/valsartan (LCZ696)
Description: matching placebo sacubitril/valsartan tablet taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: matching placebo enalapril
Description: matching placebo enalapril tablet taken orally
Study: NCT03929224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medicinal honey
Description: Treat healing surgical site with medicinal honey

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bacitracin
Description: Treat healing surgical site with bacitracin
Study: NCT03171298

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Assisted Transanal Total Mesorectal Excision
Description: * Abdominal approach with laparoscopic mobilization of the left colon~* Laparoscopic isolation and transection of inferior mesenteric vessels .~* Transabdominal dissection of the upper rectum and mesorectam.~* Insertion of transanal platform and the creation of pneumorectum.~* Occlusion of rectum 2 cm distal to the rectal lesion via purse string.~* Transanal dissection of lower and mid mesorectam~* The specimen will be extracted transanally
Study: NCT06670703

Intervention type: DIAGNOSTIC_TEST
Intervention: Obesity
Description: diagnosis as obese patients
Study: NCT03760237

Intervention type: OTHER
Intervention: observation only
Description: No intervention, observational study only
Study: NCT06669936

Intervention type: DRUG
Intervention: Fecal microbiota transplantation ± bezlotoxumab
Description: Co-administration of bezlotoxumab and FMT in patients with recurrent C. difficile infections who failed FMT alone.
Study: NCT01818323

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intra-tumoral T4 immunotherapy
Description: Intra-tumoral administration of a single dose of T4-positive patient-derived T-cells (at five escalating dose levels) contained within 1-4 mL. Cohort 6 patients receive CAR T-cells (dose level 3) after lymphodepletion with fludarabine and cyclophosphamide. Cohort 7-8 patients receive T4 cells after lymphodepletion as above, combined with 4 doses of nivolumab.
Study: NCT03567915

Intervention type: OTHER
Intervention: Evaluation of gastric volume and content
Description: The gastric volume and gastric content are assessed at 4, 5, 6, 7, and 8 hours after eating a meal.

Intervention type: OTHER
Intervention: Evaluation of gastric volume and content
Description: The gastric volume and gastric content are assessed at 4, 5, 6, 7, and 8 hours after eating a meal.
Study: NCT03164590

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: patients receive local anesthetic wound infiltration with 1 mg /kg ketamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: patients receive local anesthetic wound infiltration with 1 mg /kg ketamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dexmedetomidine
Description: patients receive local anesthetic wound infiltration with 1µg/kg dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine
Description: patients receive local anesthetic wound infiltration with 1µg/kg dexmedetomidine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bupivacaine
Description: patients receive local anesthetic wound infiltration with bupivacaine 0.5 % diluted in 20 ml saline
Study: NCT00310778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high sodium diet
Description: high sodium diet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low sodium diet
Description: low sodium diet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramipril 10 mg
Description: ramipril 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valsartan 160 mg
Description: valsartan 160 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: candesartan 8 mg
Description: candesartan 8 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atenolol 50 mg
Description: atenolol 50 mg